3.1500 0.00 (0.00%)
After hours: 4:26PM EDT
|Bid||2.7000 x 4000|
|Ask||3.1500 x 4000|
|Day's Range||2.9900 - 3.2300|
|52 Week Range||1.7600 - 9.8400|
|Beta (3Y Monthly)||2.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.67|
Conference Call to be Held at 8 a.m. ET on Monday, September 30
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.
The clinical-stage biotech appears to be in solid financial shape as it moves toward a pivotal clinical study for its lead pipeline candidate.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 9.38% and 50.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / August 2, 2019 / ImmunoGen, Inc. (NASDAQ: IMGN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 2, 2019, 2018 at 8:00 AM ...
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After its Phase 3 trial failed, ImmunoGen has opted to continue testing its ovarian cancer drug in a subgroup of patients with high rates of a protein called folate receptor alpha.
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 9 percentage points since the end of the third quarter of 2018 as investors worried over the possible ramifications of rising interest rates and escalation of the trade war with China. The hedge funds and institutional investors we track typically invest more […]
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of an in-depth operational review designed to extend the Company’s cash runway and deliver on its commitment to develop next-generation ADCs to bring more good days to patients and generate increased value for shareholders. Based on the outcomes of this review, the Company will prioritize continued development of mirvetuximab and a select portfolio of three earlier-stage product candidates targeting solid tumors and hematological malignancies. The Company will end the current quarter with approximately $240 million on its balance sheet and expects this cash, together with expense reductions resulting from the operational changes announced today and anticipated cash receipts from partners, will fund operations through the release of top-line results from the upcoming mirvetuximab Phase 3 study in platinum-resistant ovarian cancer, which are expected in the first half of 2022.
NEW YORK, NY / ACCESSWIRE / June 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of ImmunoGen, Inc. ("ImmunoGen" or the "Company") (IMGN). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether ImmunoGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...
Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.